[{"id":"983fc00c-e4fa-4493-ab00-ce5acc8c3755","acronym":"HEM-iSMART B","url":"https://clinicaltrials.gov/study/NCT05751044","created_at":"2023-03-02T15:01:24.701Z","updated_at":"2024-07-02T16:35:51.002Z","phase":"Phase 1/2","brief_title":"HEM-iSMART-B: Dasatinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological Malignancies","source_id_and_acronym":"NCT05751044 - HEM-iSMART B","lead_sponsor":"Princess Maxima Center for Pediatric Oncology","biomarkers":" ABL1 • ETV6 • NUP214 • SATB1","pipe":" | ","alterations":" NUP214-ABL1 fusion • ABL1 fusion","tags":["ABL1 • ETV6 • NUP214 • SATB1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NUP214-ABL1 fusion • ABL1 fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • dasatinib • cytarabine • cyclophosphamide • dexamethasone • dexamethasone injection"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 26","initiation":"Initiation: 10/01/2023","start_date":" 10/01/2023","primary_txt":" Primary completion: 10/01/2030","primary_completion_date":" 10/01/2030","study_txt":" Completion: 10/01/2030","study_completion_date":" 10/01/2030","last_update_posted":"2023-04-10"}]